Clinical Trial Update: Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial is evaluating a nanobody-based CD19/CD22 tandem dual CAR-T cell therapy for relapsed/refractory precursor B-cell lymphoblastic leukemia/lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Lymphoblastic Lymphoma

Drugs mentioned

• Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy

Snippet

Sponsor: Peking University People's Hospital | Conditions: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Phase 1, Phase 2 | Status: RECRUITING